No abstract available
Keywords:
Immune-checkpoint inhibitors; NSCLC; Oncogenic drivers; Predictive biomarkers; RET rearrangement.
MeSH terms
-
Brain Neoplasms / genetics
-
Brain Neoplasms / secondary
-
Brain Neoplasms / therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / secondary
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Female
-
Gene Rearrangement
-
Humans
-
Immune Checkpoint Inhibitors / therapeutic use
-
Immunotherapy*
-
Liver Neoplasms / genetics
-
Liver Neoplasms / secondary
-
Liver Neoplasms / therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Middle Aged
-
Proto-Oncogene Proteins c-ret / agonists
-
Proto-Oncogene Proteins c-ret / genetics*
-
Treatment Outcome
Substances
-
Immune Checkpoint Inhibitors
-
Proto-Oncogene Proteins c-ret
-
RET protein, human